Statement of Organization, Functions, and Delegations of Authority, 30174-30175 [2011-12570]
Download as PDF
<![CDATA[
30174
Federal Register / Vol. 76, No. 100 / Tuesday, May 24, 2011 / Notices
EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN
Number of
pharmacies
Form Name/activity
Total burden
hours
Average
hourly wage
rate *
Total cost
burden
Cognitive interviews .........................................................................................
Pretest ..............................................................................................................
Pharmacy background questionnaire ..............................................................
20
60
60
30
157
10
$32.28
22.08
51.27
$968
3,467
513
Total ..........................................................................................................
140
197
na
$4,948
* Based upon the mean of the average hourly wages for Pharmacists (29–1051; $51.27), Pharmacy Technicians (29–2052; $13.92), and Pharmacy Aides (31–9095; $10.74), National Compensation Survey: Occupational wages in the United States May 2009, ‘‘U.S. Department of Labor,
Bureau of Labor Statistics.’’ The hourly wage for the cognitive interviews is a weighted average for 10 pharmacists, 8 pharmacy technicians and
2 pharmacy aides; the hourly wage for the pretest is a weighted average for 157 pharmacists, 235 pharmacy technicians and 235 pharmacy
aides.
Estimated Annual Costs to the Federal
Government
Exhibit 3 shows the estimated total
and annualized cost for this project.
Although data collection will last for
less than one year, the entire project
will take about 3 years. The total cost for
this project is approximately $320,818.
EXHIBIT 3—ESTIMATED TOTAL AND ANNUALIZED COST
Cost component
Total cost
Annualized
cost
Project Development ...............................................................................................................................................
Data Collection Activities .........................................................................................................................................
Data Processing and Analysis .................................................................................................................................
Publication of Results ..............................................................................................................................................
Project Management ................................................................................................................................................
Overhead .................................................................................................................................................................
$65,340
62,831
11,004
15,767
7,496
158,380
$21,780
20,944
3,368
5,256
2,498
5,293
Total ..................................................................................................................................................................
320,818
106,939
jlentini on DSK4TPTVN1PROD with NOTICES
Request for Comments
In accordance with the Paperwork
Reduction Act, comments on AHRQ’s
information collection are requested
with regard to any of the following: 0(a)
Whether the proposed collection of
information is necessary for the proper
performance of AHRQ healthcare
research and healthcare information
dissemination functions, including
whether the information will have
practical utility; (b) the accuracy of
AHRQ’s estimate of burden (including
hours and costs) of the proposed
collection(s) of information; (c) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(d) ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
VerDate Mar<15>2010
16:47 May 23, 2011
Jkt 223001
Dated: May 10, 2011.
Carolyn M. Clancy,
Director.
[FR Doc. 2011–12505 Filed 5–23–11; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Interagency Committee on Smoking
and Health: Notice of Charter Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the
Interagency Committee on Smoking and
Health, Department of Health and
Human Services, has been renewed for
a 2-year period through March 20, 2013.
For information, contact Dana
Shelton, Designated Federal Officer,
Interagency Committee on Smoking and
Health, Centers for Disease Control and
Prevention, Department of Health and
Human Services, 1600 Clifton Road,
M/S K–50, Atlanta, Georgia 30333,
telephone 770/488–5709 or fax 770/
488–5767.
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: April 11, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2011–12568 Filed 5–23–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
E:\FR\FM\24MYN1.SGM
24MYN1
jlentini on DSK4TPTVN1PROD with NOTICES
Federal Register / Vol. 76, No. 100 / Tuesday, May 24, 2011 / Notices
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 76, FR 24886–24887,
dated May 3, 2011) is amended to reflect
the reorganization of the National
Center for Injury Prevention and
Control, Office of Noncommunicable
Diseases, Injury and Environmental
Health, Centers for Disease Control and
Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows:
After the title and functional
statement for the Division of Violence
Prevention (CUHC), delete in their
entirety the title and functional
statement for the Office of the Director,
(CUHC1) and insert the following:
Office of the Director, (CUHC1). (1)
Establishes and interprets policies and
determines program priorities; (2)
provides national and international
leadership and guidance in policy
formation and program planning,
development, and evaluation; (3)
provides administrative, fiscal, and
technical support for division programs
and units; (4) assures multi-disciplinary
collaboration in violence prevention
and control activities; (5) provides
leadership for developing research in
etiologic, epidemiologic, and behavioral
aspects of violence prevention and
control; (6) coordinates domestic and
international activities within the
division and with others involved in
violence prevention; (7) prepares and
monitors clearance of manuscripts for
publication in scientific and technical
journals and publications, including
articles and guidelines published in the
MMWR, and other publications for the
public; (8) prepares, tracks and
coordinates responses to all inquiries
from Congress, the public, and the
Department of Health and Human
Services; (9) develops and produces
communication tools and public affairs
strategies to meet the needs of the
division programs and mission; (10)
develops health communication
campaigns and guides the production
and distribution of print, broadcast, and
electronic materials for use in programs
at the national and state levels; (11)
provides technical assistance and
consultation to domestic and
international governmental and nongovernmental organizations on violence
prevention; and (12) establishes linkages
and collaborates, as appropriate, with
other divisions and offices in NCIPC,
other CIOs throughout CDC, and with
national and international prevention
partners that impact on violence
prevention programs.
Delete in their entirety items 10
through 13 of the functional statement
VerDate Mar<15>2010
16:47 May 23, 2011
Jkt 223001
for the Program Implementation and
Dissemination Branch (CUHCD).
Dated: May 13 2011.
William P. Nichols,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2011–12570 Filed 5–23–11; 8:45 am]
BILLING CODE 4163–18–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–1999–D–0792] (Formerly
FDA–1999–D–0792)
Draft Guidance for Clinical
Investigators, Industry, and FDA Staff:
Financial Disclosure by Clinical
Investigators; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance entitled
‘‘Guidance for Clinical Investigators,
Industry, and FDA Staff: Financial
Disclosure by Clinical Investigators.’’
This draft guidance is intended to assist
clinical investigators, industry, and FDA
staff in interpreting and complying with
the regulations governing financial
disclosure by clinical investigators. This
guidance provides FDA’s responses to
the most frequently asked questions
regarding financial disclosure by
clinical investigators.
DATES: Although comments on any
guidance can be submitted at any time
(see 21 CFR 10.115(g)(5)), to ensure that
the Agency considers a comment on this
draft guidance before it begins work on
the final version of the guidance,
electronic or written comments on the
draft guidance should be submitted by
July 25, 2011. Submit written comments
on the draft guidance to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
Submit electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance
document.
ADDRESSES: Submit written requests for
single copies of this draft guidance to
the Division of Drug Information, Center
for Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201,
Silver Spring, MD 20993–0002 (1–888–
463–6332 or 301–796–3400); or the
Office of Communication, Outreach and
SUMMARY:
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
30175
Development (HFM–40), Center for
Biologics Evaluation and Research,
Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852–
1448 (1–800–835–4709 or 301–827–
1800); or the Division of Small
Manufacturers, International, and
Consumer Assistance, Center for
Devices and Radiological Health, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, rm. 4622,
Silver Spring, MD 20993 (1–800–638–
2041 or 301–796–7100). Send one selfaddressed adhesive label to assist the
office in processing your requests.
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Marsha Melvin, Office of Good Clinical
Practice, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 32,
rm. 5170, Silver Spring, MD 20993–
0002, 301–796–8345.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance entitled ‘‘Guidance for
Clinical Investigators, Industry, and
FDA Staff: Financial Disclosure by
Clinical Investigators.’’ This guidance is
intended to assist clinical investigators,
industry, and FDA staff in interpreting
and complying with the regulations
governing financial disclosure by
clinical investigators, part 54 (21 CFR
part 54), and to provide FDA’s
responses to the most frequently asked
questions regarding financial disclosure
by clinical investigators. When
finalized, this guidance will supersede
‘‘Guidance for Industry—Financial
Disclosure by Clinical Investigators’’
(March 20, 2001, Center for Drug
Evaluation and Research, Center for
Biologics Evaluation and Research, and
Center for Devices and Radiological
Health).
This guidance also responds to
recommendations made by the Office of
the Inspector General (OIG), Department
of Health and Human Services, in their
report entitled ‘‘The Food and Drug
Administration’s Oversight of Clinical
Investigators’ Financial Information.’’ 1
The OIG’s recommendations were
intended to strengthen FDA’s oversight
1 OIG report OEI–05–07–00730 available at https://
oig.hhs.gov/oei/reports/oei-05-07-00730.pdf. (FDA
has verified the Web site address, but FDA is not
responsible for any subsequent changes to the Web
site after this document publishes in the Federal
Register.)
E:\FR\FM\24MYN1.SGM
24MYN1
]]>Agencies
[Federal Register Volume 76, Number 100 (Tuesday, May 24, 2011)]
[Notices]
[Pages 30174-30175]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-12570]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Statement of Organization, Functions, and Delegations of
Authority
Part C (Centers for Disease Control and Prevention) of the
Statement of Organization, Functions, and Delegations of Authority of
the Department of Health and Human Services (45 FR 67772-76, dated
[[Page 30175]]
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as
amended most recently at 76, FR 24886-24887, dated May 3, 2011) is
amended to reflect the reorganization of the National Center for Injury
Prevention and Control, Office of Noncommunicable Diseases, Injury and
Environmental Health, Centers for Disease Control and Prevention.
Section C-B, Organization and Functions, is hereby amended as
follows:
After the title and functional statement for the Division of
Violence Prevention (CUHC), delete in their entirety the title and
functional statement for the Office of the Director, (CUHC1) and insert
the following:
Office of the Director, (CUHC1). (1) Establishes and interprets
policies and determines program priorities; (2) provides national and
international leadership and guidance in policy formation and program
planning, development, and evaluation; (3) provides administrative,
fiscal, and technical support for division programs and units; (4)
assures multi-disciplinary collaboration in violence prevention and
control activities; (5) provides leadership for developing research in
etiologic, epidemiologic, and behavioral aspects of violence prevention
and control; (6) coordinates domestic and international activities
within the division and with others involved in violence prevention;
(7) prepares and monitors clearance of manuscripts for publication in
scientific and technical journals and publications, including articles
and guidelines published in the MMWR, and other publications for the
public; (8) prepares, tracks and coordinates responses to all inquiries
from Congress, the public, and the Department of Health and Human
Services; (9) develops and produces communication tools and public
affairs strategies to meet the needs of the division programs and
mission; (10) develops health communication campaigns and guides the
production and distribution of print, broadcast, and electronic
materials for use in programs at the national and state levels; (11)
provides technical assistance and consultation to domestic and
international governmental and non-governmental organizations on
violence prevention; and (12) establishes linkages and collaborates, as
appropriate, with other divisions and offices in NCIPC, other CIOs
throughout CDC, and with national and international prevention partners
that impact on violence prevention programs.
Delete in their entirety items 10 through 13 of the functional
statement for the Program Implementation and Dissemination Branch
(CUHCD).
Dated: May 13 2011.
William P. Nichols,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2011-12570 Filed 5-23-11; 8:45 am]
BILLING CODE 4163-18-M
